Prostate-Specific Antigen Screening and Prostate Cancer Mortality: An Emulation of Target Trials in US Medicare
Our estimates suggest that under conventional statistical criteria, annual PSA screening for 8 years is highly compatible with reductions of PC mortality from four to one fewer PC deaths per 1,000 screened men age 67-74 years. As with any study using real-world data, the estimates could be affected by residual confounding.
Authors
- Xabier García‐Albéniz (ORCID: https://orcid.org/0000-0002-9814-2343)
- Joy Shi (ORCID: https://orcid.org/0000-0002-4234-7999)
- Ruth Etzioni (ORCID: https://orcid.org/0000-0002-9164-6370)
- John Hsu
- Barbra A. Dickerman (ORCID: https://orcid.org/0000-0003-2843-687X)
- Miguel A. Hernán (ORCID: https://orcid.org/0000-0003-1619-8456)
- June M. Chan (ORCID: https://orcid.org/0000-0002-7620-569X)
Institutions
- Harvard University (US)
- University of California, San Francisco (US)
- Massachusetts General Hospital (US)
- Fred Hutch Cancer Center (US)
Publication Details
- Journal
- JCO Clinical Cancer Informatics
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1200/cci.24.00094
- Citations
- 2
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- National Institutes of Health